Axxcess Wealth Management LLC Grows Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Axxcess Wealth Management LLC grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 5.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,933 shares of the medical equipment provider’s stock after purchasing an additional 492 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Intuitive Surgical were worth $3,014,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ISRG. Portside Wealth Group LLC boosted its holdings in Intuitive Surgical by 8.2% in the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after acquiring an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Intuitive Surgical by 58.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock worth $2,805,000 after purchasing an additional 3,054 shares during the period. Kades & Cheifetz LLC acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $230,000. Blair William & Co. IL lifted its position in Intuitive Surgical by 3.1% during the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after buying an additional 11,400 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Intuitive Surgical by 21.2% during the third quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock worth $216,140,000 after buying an additional 129,194 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Jefferies Financial Group upped their price target on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research report on Friday, April 19th. BTIG Research upped their price target on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Royal Bank of Canada lifted their price objective on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research note on Wednesday, January 24th. Robert W. Baird decreased their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Finally, Citigroup lifted their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus target price of $396.17.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG traded up $3.71 during trading on Friday, reaching $381.36. 1,028,858 shares of the company’s stock traded hands, compared to its average volume of 1,492,254. The company has a 50 day moving average of $385.40 and a 200-day moving average of $349.30. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $403.76. The stock has a market capitalization of $135.27 billion, a P/E ratio of 68.84, a price-to-earnings-growth ratio of 4.93 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s quarterly revenue was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.00 EPS. Equities research analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the sale, the executive vice president now directly owns 5,507 shares in the company, valued at $2,037,149.44. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director Alan J. Levy sold 2,000 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.70, for a total transaction of $741,400.00. Following the completion of the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Robert Desantis sold 1,498 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the sale, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,037,149.44. The disclosure for this sale can be found here. Insiders sold 226,928 shares of company stock worth $87,833,828 in the last 90 days. Corporate insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.